

Background

Secukinumab is a recently approved interleukin 17A inhibitor authorized by the Autonomic Pharmacotherapeutic Commission of the Balearic Islands for the treatment of :

1. Moderate to severe plaque psoriasis in adults candidates for systemic treatment, after inadequate response, contraindication or intolerance to at least two conventional treatments or PUVA.
2. Psoriatic arthritis or ankylosing spondylarthritis in a patient who has not responded to conventional therapy.

Purpose

The aim of the study was to assess the early effectiveness and safety of secukinumab in patients with psoriasis.

Material and methods

Retrospective study from December 2015 (when drug was introduced in the hospital) to may 2017

- Inclusion criteria: Patients with psoriasis who started treatment with secukinumab during the study period.
- Variables collected: demographic, indication and previous treatment.
- Evaluation of efficacy: response at week 12 (± 4 weeks).
Cut-off date 31/08/2017.

Results

Demographic



60 patients (38 males) with moderate or severe psoriasis.
Median age: 51.1 ± 12.2 years

Clinical

56 cases of plaque psoriasis
(5 cases of psoriatic arthritis)


4 cases of other psoriasis
(1 case of psoriatic arthritis)

Previous Treatment

| | Non-biological systemic therapy | Phototherapy | Biological therapy |
|-------------------|---------------------------------|--------------|--------------------|
| Yes | 56 | 27 | 43 |
| No | 1 | 29 | 17 |
| No data available | 3 | 4 | 0 |

Efficacy

Response after 12 weeks of treatment



Safety

– One patient experienced injection-site-reaction, even though it did not lead to treatment discontinuation.

Conclusion

- Secukinumab shows high efficacy, achieving completely clear skin in more than 50% of patients at week 12, both in naive patients and in those who failed prior biologics.
- Secukinumab is well tolerated, with a good safety profile and without discontinuations due to adverse event.
- Therefore, it can be considered as a good therapeutic option in patients with moderate to severe psoriasis that are non-responders or have contraindication or intolerance to systemic treatments or phototherapy.